Registry Search

ARANELLE

Comprehensive clinical and safety monograph for ARANELLE (ARANELLE).

ARANESP

Comprehensive clinical and safety monograph for ARANESP (ARANESP).

ARAVA

Comprehensive clinical and safety monograph for ARAVA (ARAVA).

ARAZLO

Comprehensive clinical and safety monograph for ARAZLO (ARAZLO).

ARBLI

Comprehensive clinical and safety monograph for ARBLI (ARBLI).

ARCALYST

Comprehensive clinical and safety monograph for ARCALYST (ARCALYST).

ARCAPTA NEOHALER

Comprehensive clinical and safety monograph for ARCAPTA NEOHALER (ARCAPTA NEOHALER).

ARDUAN

Comprehensive clinical and safety monograph for ARDUAN (ARDUAN).

AREDIA

Comprehensive clinical and safety monograph for AREDIA (AREDIA).

ARESTIN

Comprehensive clinical and safety monograph for ARESTIN (ARESTIN).

ARESTOCAINE HYDROCHLORIDE

Comprehensive clinical and safety monograph for ARESTOCAINE HYDROCHLORIDE (ARESTOCAINE HYDROCHLORIDE).

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Comprehensive clinical and safety monograph for ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN (ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN).

ARFONAD

Comprehensive clinical and safety monograph for ARFONAD (ARFONAD).

ARFORMOTEROL TARTRATE

Other adrenergic drugs can have additive cardiovascular effects Can cause paradoxical bronchospasm and increase the risk of asthma-related death.

ARGATROBAN

Comprehensive clinical and safety monograph for ARGATROBAN (ARGATROBAN).

ARGATROBAN IN 0.9% SODIUM CHLORIDE

No significant drug interactions Can cause hypernatremia and fluid overload.

ARGATROBAN IN DEXTROSE

Comprehensive clinical and safety monograph for ARGATROBAN IN DEXTROSE (ARGATROBAN IN DEXTROSE).

ARGATROBAN IN SODIUM CHLORIDE

No significant drug interactions Can cause hypernatremia and fluid overload.

ARICEPT

Comprehensive clinical and safety monograph for ARICEPT (ARICEPT).

ARICEPT ODT

Comprehensive clinical and safety monograph for ARICEPT ODT (ARICEPT ODT).

ARIDOL

Comprehensive clinical and safety monograph for ARIDOL (ARIDOL).

ARIDOL KIT

Comprehensive clinical and safety monograph for ARIDOL KIT (ARIDOL KIT).

ARIKAYCE KIT

Comprehensive clinical and safety monograph for ARIKAYCE KIT (ARIKAYCE KIT).

ARIMIDEX

Comprehensive clinical and safety monograph for ARIMIDEX (ARIMIDEX).

ARIPIPRAZOLE

Strong CYP3A4 inhibitors (eg ketoconazole) or inducers (eg carbamazepine) require dose adjustment May cause suicidal thoughts and metabolic changes including weight gain and dyslipidemia.

ARISTADA

Comprehensive clinical and safety monograph for ARISTADA (ARISTADA).

ARISTADA INITIO KIT

Comprehensive clinical and safety monograph for ARISTADA INITIO KIT (ARISTADA INITIO KIT).

ARISTOCORT

Comprehensive clinical and safety monograph for ARISTOCORT (ARISTOCORT).

ARISTOCORT A

Comprehensive clinical and safety monograph for ARISTOCORT A (ARISTOCORT A).

ARISTOGEL

Comprehensive clinical and safety monograph for ARISTOGEL (ARISTOGEL).

ARISTOSPAN

Comprehensive clinical and safety monograph for ARISTOSPAN (ARISTOSPAN).

ARIXTRA

Comprehensive clinical and safety monograph for ARIXTRA (ARIXTRA).

ARMLUPEG

Comprehensive clinical and safety monograph for ARMLUPEG (ARMLUPEG).

ARMODAFINIL

Induces CYP3A4 and inhibits CYP2C19 affecting many drugs Can cause serious skin reactions and psychiatric symptoms.

ARMONAIR DIGIHALER

Comprehensive clinical and safety monograph for ARMONAIR DIGIHALER (ARMONAIR DIGIHALER).

ARMONAIR RESPICLICK

Comprehensive clinical and safety monograph for ARMONAIR RESPICLICK (ARMONAIR RESPICLICK).

ARNUITY ELLIPTA

Comprehensive clinical and safety monograph for ARNUITY ELLIPTA (ARNUITY ELLIPTA).

AROMASIN

Comprehensive clinical and safety monograph for AROMASIN (AROMASIN).

ARRANON

Comprehensive clinical and safety monograph for ARRANON (ARRANON).

ARSENIC TRIOXIDE

Comprehensive clinical and safety monograph for ARSENIC TRIOXIDE (ARSENIC TRIOXIDE).

ARTANE

Comprehensive clinical and safety monograph for ARTANE (ARTANE).

Artemether-Lumefantrine

Artemether-lumefantrine (AL) is a fixed-dose artemisinin-based combination therapy (ACT) and the WHO-recommended first-line treatment for uncomplicated Plasmodium falciparum malaria in the second and third trimesters of pregnancy. In the first trimester, data are more limited but increasingly reassuring: large observational studies including the WHO-coordinated WWARN database and the PREGACT trial have not demonstrated increased rates of miscarriage, stillbirth, or major congenital malformations compared to quinine. WHO updated guidance (2015, reaffirmed 2023) endorses ACT use — including AL — in the first trimester when it is the only available effective treatment, acknowledging that untreated or undertreated falciparum malaria in pregnancy carries high risks of maternal death, severe anaemia, hypoglycaemia, pulmonary oedema, cerebral malaria, miscarriage, preterm birth, fetal growth restriction, and perinatal death. Quinine plus clindamycin remains the preferred regimen in settings where first-trimester ACT alternatives exist and clinical capacity allows. The drug is not indicated for severe or complicated malaria (IV artesunate is the standard of care) or for non-falciparum species without falciparum co-infection.

ARTESUNATE

Comprehensive clinical and safety monograph for ARTESUNATE (ARTESUNATE).

ARTHROTEC

Comprehensive clinical and safety monograph for ARTHROTEC (ARTHROTEC).

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

Beta-blockers may antagonize cardiac effects and cause severe hypertension Can cause angina and arrhythmias in patients with heart disease.

ARYMO ER

Comprehensive clinical and safety monograph for ARYMO ER (ARYMO ER).

ARYNTA

Comprehensive clinical and safety monograph for ARYNTA (ARYNTA).

ARZERRA

Comprehensive clinical and safety monograph for ARZERRA (ARZERRA).

ASACOL

Comprehensive clinical and safety monograph for ASACOL (ASACOL).

ASACOL HD

Comprehensive clinical and safety monograph for ASACOL HD (ASACOL HD).